Innovative neuroprotective therapy ARG-007 shows promise in reducing brain cell death post-stroke, poised for phase one clinical trial |Dr Liz Dallimore , CEO, Argenica Therapeutics Ltd. 00:10:00

Share On Facebook Share On Twitter

Novel neuroprotective therapy ARG-007 demonstrates potential in reducing brain cell damage after stroke, advancing towards phase one clinical trial following successful IPO funding.

Recent Videos